On Tuesday, Mereo Biopharma Group Plc ADR (NASDAQ: MREO) was -4.96% drop from the session before settling in for the closing price of $3.63. A 52-week range for MREO has been $1.07 – $4.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -20.00% over the last five years. When this article was written, the company’s average yearly earnings per share was at 30.00%. With a float of $140.27 million, this company’s outstanding shares have now reached $140.27 million.
The firm has a total of 33 workers. Let’s measure their productivity.
Mereo Biopharma Group Plc ADR (MREO) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Mereo Biopharma Group Plc ADR stocks. The insider ownership of Mereo Biopharma Group Plc ADR is 0.00%, while institutional ownership is 61.21%. The most recent insider transaction that took place on Jun 26 ’24, was worth 313,101. In this transaction Chief Executive Officer of this company sold 92,273 shares at a rate of $3.39, taking the stock ownership to the 709,518 shares. Before that another transaction happened on Jun 26 ’24, when Company’s General Counsel sold 32,187 for $3.39, making the entire transaction worth $109,217. This insider now owns 184,387 shares in total.
Mereo Biopharma Group Plc ADR (MREO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 30.00% per share during the next fiscal year.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Trading Performance Indicators
You can see what Mereo Biopharma Group Plc ADR (MREO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.86. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.25, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach -0.04 in one year’s time.
Technical Analysis of Mereo Biopharma Group Plc ADR (MREO)
Analysing the last 5-days average volume posted by the [Mereo Biopharma Group Plc ADR, MREO], we can find that recorded value of 1.31 million was lower than the volume posted last year of 1.43 million. As of the previous 9 days, the stock’s Stochastic %D was 28.84%. Additionally, its Average True Range was 0.28.
During the past 100 days, Mereo Biopharma Group Plc ADR’s (MREO) raw stochastic average was set at 46.84%, which indicates a significant increase from 15.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.84% in the past 14 days, which was higher than the 62.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.33, while its 200-day Moving Average is $2.77. Now, the first resistance to watch is $3.66. This is followed by the second major resistance level at $3.87. The third major resistance level sits at $3.98. If the price goes on to break the first support level at $3.34, it is likely to go to the next support level at $3.23. Should the price break the second support level, the third support level stands at $3.02.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Key Stats
There are 140,257K outstanding shares of the company, which has a market capitalization of 483.93 million. As of now, sales total 10,000 K while income totals -29,470 K. Its latest quarter income was 0 K while its last quarter net income were -8,950 K.
